00001057702024FYfalsehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://www.westpharma.com/20241231#OtherIncomeExpensehttp://www.westpharma.com/20241231#OtherIncomeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purewst:instancewst:fiscal_quarterwst:trancheiso4217:SGDiso4217:EURiso4217:JPYutr:bbliso4217:USDwst:bblwst:planwst:facilitywst:segment00001057702024-01-012024-12-3100001057702024-06-3000001057702025-02-0600001057702023-01-012023-12-3100001057702022-01-012022-12-3100001057702024-12-3100001057702023-12-310000105770us-gaap:CommonStockMember2021-12-310000105770us-gaap:AdditionalPaidInCapitalMember2021-12-310000105770us-gaap:TreasuryStockCommonMember2021-12-310000105770us-gaap:RetainedEarningsMember2021-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100001057702021-12-310000105770us-gaap:RetainedEarningsMember2022-01-012022-12-310000105770us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000105770us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:CommonStockMember2022-12-310000105770us-gaap:AdditionalPaidInCapitalMember2022-12-310000105770us-gaap:TreasuryStockCommonMember2022-12-310000105770us-gaap:RetainedEarningsMember2022-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100001057702022-12-310000105770us-gaap:RetainedEarningsMember2023-01-012023-12-310000105770us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000105770us-gaap:TreasuryStockCommonMember2023-01-012023-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:CommonStockMember2023-12-310000105770us-gaap:AdditionalPaidInCapitalMember2023-12-310000105770us-gaap:TreasuryStockCommonMember2023-12-310000105770us-gaap:RetainedEarningsMember2023-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000105770us-gaap:RetainedEarningsMember2024-01-012024-12-310000105770us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310000105770us-gaap:TreasuryStockCommonMember2024-01-012024-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:CommonStockMember2024-12-310000105770us-gaap:AdditionalPaidInCapitalMember2024-12-310000105770us-gaap:TreasuryStockCommonMember2024-12-310000105770us-gaap:RetainedEarningsMember2024-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000105770srt:MinimumMember2024-12-310000105770srt:MaximumMember2024-12-310000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductComponentsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductComponentsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductComponentsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductDeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductDeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductDeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-3100001057702023-02-280000105770us-gaap:LandMember2024-12-310000105770us-gaap:LandMember2023-12-310000105770srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-12-310000105770srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-12-310000105770us-gaap:BuildingAndBuildingImprovementsMember2024-12-310000105770us-gaap:BuildingAndBuildingImprovementsMember2023-12-310000105770srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000105770srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000105770us-gaap:MachineryAndEquipmentMember2024-12-310000105770us-gaap:MachineryAndEquipmentMember2023-12-310000105770srt:MinimumMemberus-gaap:ToolsDiesAndMoldsMember2024-12-310000105770srt:MaximumMemberus-gaap:ToolsDiesAndMoldsMember2024-12-310000105770us-gaap:ToolsDiesAndMoldsMember2024-12-310000105770us-gaap:ToolsDiesAndMoldsMember2023-12-310000105770srt:MinimumMemberwst:ComputerHardwareAndSoftwareMember2024-12-310000105770srt:MaximumMemberwst:ComputerHardwareAndSoftwareMember2024-12-310000105770wst:ComputerHardwareAndSoftwareMember2024-12-310000105770wst:ComputerHardwareAndSoftwareMember2023-12-310000105770us-gaap:ConstructionInProgressMember2024-12-310000105770us-gaap:ConstructionInProgressMember2023-12-310000105770wst:WestCompanyMexicoSADeCVMember2024-12-310000105770wst:AluplastSADeCVMember2024-12-310000105770wst:PharmaTapSADeCVMember2024-12-310000105770wst:PharmaRubberSADeCVMember2024-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2024-12-310000105770srt:AffiliatedEntityMember2024-12-310000105770srt:AffiliatedEntityMember2023-12-310000105770wst:DistributorshipAgreementMember2024-01-012024-12-310000105770wst:DistributorshipAgreementMember2023-01-012023-12-310000105770wst:DistributorshipAgreementMember2022-01-012022-12-310000105770srt:AffiliatedEntityMember2024-01-012024-12-310000105770srt:AffiliatedEntityMember2023-01-012023-12-310000105770srt:AffiliatedEntityMember2022-01-012022-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2023-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2022-12-310000105770wst:ProprietaryProductsMember2022-12-310000105770wst:ContractManufacturedProductsMember2022-12-310000105770wst:ProprietaryProductsMember2023-01-012023-12-310000105770wst:ContractManufacturedProductsMember2023-01-012023-12-310000105770wst:ProprietaryProductsMember2023-12-310000105770wst:ContractManufacturedProductsMember2023-12-310000105770wst:ProprietaryProductsMember2024-01-012024-12-310000105770wst:ContractManufacturedProductsMember2024-01-012024-12-310000105770wst:ProprietaryProductsMember2024-12-310000105770wst:ContractManufacturedProductsMember2024-12-310000105770wst:PatentsAndLicensingMember2024-12-310000105770wst:PatentsAndLicensingMember2023-12-310000105770us-gaap:TechnologyBasedIntangibleAssetsMember2024-12-310000105770us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000105770us-gaap:TrademarksMember2024-12-310000105770us-gaap:TrademarksMember2023-12-310000105770us-gaap:CustomerRelationshipsMember2024-12-310000105770us-gaap:CustomerRelationshipsMember2023-12-310000105770us-gaap:CustomerContractsMember2024-12-310000105770us-gaap:CustomerContractsMember2023-12-310000105770wst:TermLoanDue2027Member2024-12-310000105770wst:TermLoanDue2027Member2023-12-310000105770wst:TermLoanDue2024Member2024-12-310000105770wst:TermLoanDue2024Member2023-12-310000105770wst:SeniorBNotesDue2024Member2024-12-310000105770wst:SeniorBNotesDue2024Member2023-12-310000105770wst:SeniorCNotesDue2027Member2024-12-310000105770wst:SeniorCNotesDue2027Member2023-12-310000105770wst:RevolvingCreditFacilityDue2024Member2022-02-280000105770wst:RevolvingCreditFacilityDue2024Member2022-03-310000105770us-gaap:DomesticLineOfCreditMemberwst:RevolvingCreditFacilityDue2024Member2022-03-310000105770us-gaap:ForeignLineOfCreditMemberwst:RevolvingCreditFacilityDue2024Member2022-03-310000105770wst:RevolvingCreditFacilityDue2024Member2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberwst:ApplicableMarginMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:FederalFundsEffectiveSwapRateMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:BaseRateMembersrt:MinimumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:BaseRateMembersrt:MaximumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Member2024-01-012024-12-310000105770wst:RevolvingCreditFacilityDue2024Member2023-01-012023-12-310000105770wst:RevolvingCreditFacilityDue2024Member2024-12-310000105770us-gaap:LetterOfCreditMemberwst:RevolvingCreditFacilityDue2024Member2024-12-310000105770wst:TermLoanDue2027Member2024-07-020000105770wst:TermLoanDue2024Member2024-07-022024-07-020000105770wst:SeniorBNotesDue2024Member2024-07-022024-07-020000105770wst:SeniorBNotesDue2024Member2012-07-050000105770srt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-022024-07-020000105770srt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-022024-07-020000105770srt:MinimumMemberus-gaap:BaseRateMember2024-07-022024-07-020000105770srt:MaximumMemberus-gaap:BaseRateMember2024-07-022024-07-020000105770us-gaap:SecuredOvernightFinancingRateSofrMember2024-07-022024-07-020000105770wst:TermLoanDue2024Member2024-01-012024-12-310000105770wst:TermLoanDue2024Member2023-01-012023-12-310000105770us-gaap:SeniorNotesMember2012-12-3100001057702012-12-310000105770wst:SeniorNotesDue2022Memberus-gaap:SeniorNotesMember2012-12-310000105770wst:SeniorBNotesDue2024Memberus-gaap:SeniorNotesMember2012-12-310000105770wst:SeniorCNotesDue2027Memberus-gaap:SeniorNotesMember2012-12-310000105770us-gaap:SeniorNotesMember2024-12-310000105770us-gaap:SeniorNotesMember2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:SGD2024-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:USD2024-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:SGD2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:USD2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:EUR2024-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:USD2024-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:EUR2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:SGD2023-12-310000105770us-gaap:ForeignExchangeForwardMember2024-01-012024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPY2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPY2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SGD2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SGD2024-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2019-12-012019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2024-07-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2024-12-310000105770us-gaap:OptionMember2024-12-310000105770wst:OtherExpenseIncomeMember2024-01-012024-12-310000105770wst:OtherExpenseIncomeMember2023-01-012023-12-310000105770wst:OtherExpenseIncomeMember2022-01-012022-12-310000105770us-gaap:FairValueHedgingMember2024-01-012024-12-310000105770us-gaap:FairValueHedgingMember2023-01-012023-12-310000105770us-gaap:FairValueHedgingMember2022-01-012022-12-310000105770srt:ScenarioForecastMemberus-gaap:FairValueHedgingMember2025-01-012025-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2024-01-012024-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2023-01-012023-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2022-01-012022-12-310000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2024-01-012024-12-310000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-12-310000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-12-310000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2024-01-012024-12-310000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-12-310000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-12-310000105770us-gaap:TreasuryLockMember2024-01-012024-12-310000105770us-gaap:TreasuryLockMember2023-01-012023-12-310000105770us-gaap:TreasuryLockMember2022-01-012022-12-310000105770us-gaap:CurrencySwapMember2024-01-012024-12-310000105770us-gaap:CurrencySwapMember2023-01-012023-12-310000105770us-gaap:CurrencySwapMember2022-01-012022-12-310000105770wst:NetSalesMember2024-01-012024-12-310000105770wst:NetSalesMember2023-01-012023-12-310000105770wst:NetSalesMember2022-01-012022-12-310000105770us-gaap:CostOfSalesMember2024-01-012024-12-310000105770us-gaap:CostOfSalesMember2023-01-012023-12-310000105770us-gaap:CostOfSalesMember2022-01-012022-12-310000105770us-gaap:InterestExpenseMember2024-01-012024-12-310000105770us-gaap:InterestExpenseMember2023-01-012023-12-310000105770us-gaap:InterestExpenseMember2022-01-012022-12-310000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2024-01-012024-12-310000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2023-01-012023-12-310000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2022-01-012022-12-310000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2024-01-012024-12-310000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2023-01-012023-12-310000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2022-01-012022-12-310000105770us-gaap:NondesignatedMember2024-01-012024-12-310000105770us-gaap:NondesignatedMember2023-01-012023-12-310000105770us-gaap:NondesignatedMember2022-01-012022-12-310000105770us-gaap:FairValueInputsLevel1Member2024-12-310000105770us-gaap:FairValueInputsLevel2Member2024-12-310000105770us-gaap:FairValueInputsLevel3Member2024-12-310000105770us-gaap:MoneyMarketFundsMember2024-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2024-12-310000105770us-gaap:BankTimeDepositsMember2024-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2024-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member2024-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member2024-12-310000105770us-gaap:CurrencySwapMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember2024-12-310000105770us-gaap:CommodityMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityMember2024-12-310000105770us-gaap:ForeignExchangeContractMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2024-12-310000105770us-gaap:FairValueInputsLevel1Member2023-12-310000105770us-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:MoneyMarketFundsMember2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:BankTimeDepositsMember2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:ForeignExchangeContractMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2021-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2022-01-012022-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2022-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2023-01-012023-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2023-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2024-01-012024-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2024-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:EmployeeStockOptionMember2024-01-012024-12-310000105770wst:AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember2024-01-012024-12-310000105770wst:StockOptionAndAppreciationRightsMember2024-01-012024-12-310000105770wst:StockOptionAndAppreciationRightsMember2023-01-012023-12-310000105770wst:StockOptionAndAppreciationRightsMember2022-01-012022-12-310000105770us-gaap:PerformanceSharesMember2024-01-012024-12-310000105770us-gaap:PerformanceSharesMember2023-01-012023-12-310000105770us-gaap:PerformanceSharesMember2022-01-012022-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2024-01-012024-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2023-01-012023-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2022-01-012022-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2024-01-012024-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2023-01-012023-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2022-01-012022-12-310000105770us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000105770us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000105770wst:StockSettledPSUAwardsMember2023-12-310000105770wst:StockSettledPSUAwardsMember2024-01-012024-12-310000105770wst:StockSettledPSUAwardsMember2024-12-310000105770wst:StockSettledPSUAwardsMembersrt:MinimumMember2024-01-012024-12-310000105770wst:StockSettledPSUAwardsMembersrt:MaximumMember2024-01-012024-12-310000105770wst:StockSettledPSUAwardsMember2023-01-012023-12-310000105770wst:StockSettledPSUAwardsMember2022-01-012022-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2024-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2024-01-012024-12-310000105770srt:DirectorMemberus-gaap:DeferredCompensationShareBasedPaymentsMember2024-01-012024-12-310000105770srt:DirectorMemberus-gaap:DeferredCompensationShareBasedPaymentsMember2023-01-012023-12-310000105770srt:DirectorMemberus-gaap:DeferredCompensationShareBasedPaymentsMember2022-01-012022-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2024-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2023-12-310000105770us-gaap:RestrictedStockMember2024-01-012024-12-310000105770us-gaap:RestrictedStockMember2023-01-012023-12-310000105770us-gaap:RestrictedStockMember2022-01-012022-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000105770country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000105770country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000105770country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000105770country:US2022-01-012022-12-310000105770country:US2023-01-012023-12-310000105770country:US2024-01-012024-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2023-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2022-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2024-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000105770us-gaap:ForeignPlanMember2024-12-310000105770us-gaap:ForeignPlanMember2023-12-310000105770country:US2024-12-310000105770country:US2023-12-310000105770srt:ScenarioForecastMember2031-01-012031-12-310000105770us-gaap:ForeignPlanMember2024-01-012024-12-310000105770us-gaap:ForeignPlanMember2023-01-012023-12-310000105770us-gaap:ForeignPlanMember2022-01-012022-12-310000105770srt:WeightedAverageMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770srt:WeightedAverageMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000105770us-gaap:DefinedBenefitPlanDebtSecurityMember2023-12-310000105770us-gaap:OtherInvestmentsMember2024-12-310000105770us-gaap:OtherInvestmentsMember2023-12-310000105770us-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770srt:MinimumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770srt:MaximumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770srt:MinimumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000105770srt:MaximumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000105770srt:MinimumMemberus-gaap:OtherInvestmentsMember2024-12-310000105770srt:MaximumMemberus-gaap:OtherInvestmentsMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanCashMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:MutualFundMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:MutualFundMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:MutualFundMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberwst:OtherMutualFundsMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberwst:OtherMutualFundsMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberwst:OtherMutualFundsMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberwst:OtherMutualFundsMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Member2024-12-310000105770us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanCashMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashMember2023-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:MutualFundMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:MutualFundMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:MutualFundMember2023-12-310000105770us-gaap:FairValueInputsLevel12And3Memberwst:OtherMutualFundsMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberwst:OtherMutualFundsMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberwst:OtherMutualFundsMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberwst:OtherMutualFundsMember2023-12-310000105770us-gaap:FairValueInputsLevel12And3Member2023-12-310000105770us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-3100001057702022-12-012022-12-310000105770us-gaap:EmployeeSeveranceMemberwst:The2022RestructuringPlanMember2023-12-310000105770us-gaap:OtherRestructuringMemberwst:The2022RestructuringPlanMember2023-12-310000105770wst:The2022RestructuringPlanMember2023-12-310000105770us-gaap:EmployeeSeveranceMemberwst:The2022RestructuringPlanMember2024-01-012024-12-310000105770us-gaap:OtherRestructuringMemberwst:The2022RestructuringPlanMember2024-01-012024-12-310000105770wst:The2022RestructuringPlanMember2024-01-012024-12-310000105770us-gaap:EmployeeSeveranceMemberwst:The2022RestructuringPlanMember2024-12-310000105770us-gaap:OtherRestructuringMemberwst:The2022RestructuringPlanMember2024-12-310000105770wst:The2022RestructuringPlanMember2024-12-3100001057702023-04-012023-06-300000105770us-gaap:StateAndLocalJurisdictionMember2024-12-310000105770us-gaap:ForeignCountryMember2024-12-310000105770wst:Year2025Memberus-gaap:StateAndLocalJurisdictionMember2024-12-310000105770wst:ThereafterMemberus-gaap:StateAndLocalJurisdictionMember2024-12-310000105770us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2019-12-3100001057702019-12-310000105770us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2024-12-310000105770country:DE2024-12-310000105770us-gaap:InsuranceClaimsMember2024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2024-01-012024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2023-01-012023-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2022-01-012022-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2024-01-012024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2023-01-012023-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2022-01-012022-12-310000105770us-gaap:IntersegmentEliminationMember2024-01-012024-12-310000105770us-gaap:IntersegmentEliminationMember2023-01-012023-12-310000105770us-gaap:IntersegmentEliminationMember2022-01-012022-12-310000105770wst:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770country:US2024-01-012024-12-310000105770country:US2023-01-012023-12-310000105770country:US2022-01-012022-12-310000105770country:US2024-12-310000105770country:US2023-12-310000105770country:DE2024-01-012024-12-310000105770country:DE2023-01-012023-12-310000105770country:DE2022-01-012022-12-310000105770country:DE2023-12-310000105770country:IE2024-01-012024-12-310000105770country:IE2023-01-012023-12-310000105770country:IE2022-01-012022-12-310000105770country:IE2024-12-310000105770country:IE2023-12-310000105770country:FR2024-01-012024-12-310000105770country:FR2023-01-012023-12-310000105770country:FR2022-01-012022-12-310000105770country:FR2024-12-310000105770country:FR2023-12-310000105770wst:OtherEuropeCountriesMember2024-01-012024-12-310000105770wst:OtherEuropeCountriesMember2023-01-012023-12-310000105770wst:OtherEuropeCountriesMember2022-01-012022-12-310000105770wst:OtherEuropeCountriesMember2024-12-310000105770wst:OtherEuropeCountriesMember2023-12-310000105770wst:OtherCountriesMember2024-01-012024-12-310000105770wst:OtherCountriesMember2023-01-012023-12-310000105770wst:OtherCountriesMember2022-01-012022-12-310000105770wst:OtherCountriesMember2024-12-310000105770wst:OtherCountriesMember2023-12-310000105770us-gaap:OperatingSegmentsMember2024-01-012024-12-310000105770us-gaap:OperatingSegmentsMember2023-01-012023-12-310000105770us-gaap:OperatingSegmentsMember2022-01-012022-12-310000105770wst:CorporateAndReconcilingItemsMember2024-01-012024-12-310000105770wst:CorporateAndReconcilingItemsMember2023-01-012023-12-310000105770wst:CorporateAndReconcilingItemsMember2022-01-012022-12-310000105770us-gaap:SellingGeneralAndAdministrativeExpensesMemberwst:CorporateAndReconcilingItemsMember2024-01-012024-12-310000105770wst:OtherExpenseIncomeMemberwst:CorporateAndReconcilingItemsMember2024-01-012024-12-310000105770wst:OtherExpenseIncomeMemberwst:CorporateAndReconcilingItemsMember2023-01-012023-12-310000105770us-gaap:CostOfSalesMemberwst:CorporateAndReconcilingItemsMember2023-01-012023-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2023-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2023-12-310000105770wst:CorporateAndReconcilingItemsMember2024-12-310000105770wst:CorporateAndReconcilingItemsMember2023-12-3100001057702024-10-012024-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-01-012024-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-12-310000105770us-gaap:AllowanceForCreditLossMember2023-12-310000105770us-gaap:AllowanceForCreditLossMember2024-01-012024-12-310000105770us-gaap:AllowanceForCreditLossMember2024-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-310000105770us-gaap:AllowanceForCreditLossMember2022-12-310000105770us-gaap:AllowanceForCreditLossMember2023-01-012023-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-01-012022-12-310000105770us-gaap:AllowanceForCreditLossMember2021-12-310000105770us-gaap:AllowanceForCreditLossMember2022-01-012022-12-31

or

☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Registrant’s telephone number, including area code: 610-594-2900

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes ☑ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.                                Yes þ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                                            Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                    ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.                            ☑

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes ☐    No ☑

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.     ☐

Indicate by check mark whether any such corrections are restatements that triggered a compensation recovery analysis during the fiscal year.    ☐

The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2024 was approximately $23.9 billion based on the closing price as reported on the New York Stock Exchange.

As of February 6, 2025, there were 72,303,766 shares of the registrant’s common stock outstanding.

Unless otherwise indicated, or the context otherwise requires, references in this report to “the Company,” “we,” “us,” “our” and “West” refer to West Pharmaceutical Services, Inc. and its majority-owned subsidiaries.

All trademarks and registered trademarks used in this report are our property, either directly or indirectly through our subsidiaries, unless noted otherwise. Daikyo Crystal Zenith® (“Crystal Zenith”) is a registered trademark of Daikyo Seiko, Ltd. (“Daikyo”).

Throughout this report, references to “Notes” refer to the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K (“Form 10-K”), unless otherwise indicated.

Information in this Form 10-K is current as of February 18, 2025, unless otherwise specified.

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies in the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.

Our business operations are organized into two global business segments, Proprietary Products and Contract-Manufactured Products.

Our Proprietary Products reportable segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. Our packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability with active drug products, while also supporting operational efficiency for customers. These packaging products also include syringe and cartridge components, including custom solutions for the specific needs of injectable drug applications, as well as administration systems that can enhance the safe delivery of drugs through advanced reconstitution, mixing and transfer technologies. We also provide films, coatings, washing, vision inspection and sterilization processes and services to enhance the quality of our packaging products and mitigate the risk of contamination and compatibility issues.

This segment’s product portfolio also includes drug containment solutions, including Crystal Zenith, a cyclic olefin polymer, in the form of vials, syringes and cartridges. These products can provide a high-quality solution to glass incompatibility issues and can stand up to cold storage environments, while reducing the risk of breakage that exists with glass. In addition, we offer a variety of self-injection devices, designed to address the need to provide at-home delivery of injectable therapies. These devices are patient-centric technologies that are easy-to-use and can be combined with connected health technologies that have the potential to increase adherence.

In addition to our Proprietary Products product portfolio, we provide our customers with a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. Offering the combination of primary proprietary packaging components, containment solutions, and drug delivery devices, as well as a broad range of integrated services, helps to position us as a leader in the integrated containment and delivery of injectable medicines.

This reportable segment has manufacturing facilities in North and South America, Europe, and Asia, with affiliated companies in Mexico and Japan. Please refer to Item 2, Properties, for additional information on our manufacturing and other sites.

Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. These products include a variety of custom contract-manufacturing and assembly solutions, which use technologies such as multi-component molding, in-mold labeling, ultrasonic welding, clean room molding, device assembly, and drug handling capabilities. We manufacture customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

We have vast expertise in product design and development, including in-house mold design, process design and validation and high-speed automated assemblies.

This reportable segment has manufacturing facilities in North America and Europe. Please refer to Item 2, Properties, for additional information on our manufacturing and other sites.

We have significant operations outside of the United States (“U.S.”), which are managed through the same business segments as our U.S. operations – Proprietary Products and Contract-Manufactured Products. Sales outside of the U.S. accounted for 57.5% of our net sales in 2024.

Although the general business processes are similar to the domestic business, international operations are exposed to additional risks. These risks include currency fluctuations relative to the U.S. Dollar (“USD”) and multiple tax jurisdictions.

See further discussion of our international operations, the risks associated with our international operations, and our attempt to minimize some of these risks in Part I, Item 1A, Risk Factors; Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations under the caption Financial Condition, Liquidity and Capital Resources; Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk; Note 1, Basis of Presentation and Summary of Significant Accounting Policies under the captions Financial Instruments and Foreign Currency Translation; and Note 11, Derivative Financial Instruments.

We use three basic raw materials in the manufacture of our products: elastomers, aluminum and plastic. Elastomers include both synthetic and natural materials. We currently have access to adequate supplies of these raw materials to meet our production needs through agreements with suppliers. We are required to carry significant amounts of inventory to meet customer requirements. In addition, some of our supply agreements require us to purchase inventory in bulk orders, which increases inventory levels but decreases the risk of supply interruption.

We employ a supply chain management strategy in our business segments, which involves purchasing from integrated suppliers that control their own sources of supply. Due to regulatory control over our production processes, sole source availability, and the cost and time involved in qualifying suppliers, we rely on single-source suppliers for many critical raw materials. We generally purchase certain raw materials in the open market and therefore the results of our operations may be affected by price fluctuations. This strategy increases the risk that our supply chain may be interrupted in the event of a supplier production or distribution problem. These risks are managed, when and where possible, by selecting suppliers with multiple manufacturing sites, rigorous quality control systems, surplus inventory levels and other methods of maintaining supply in case of an interruption in production or distribution. Heightened inflation may result in unfavorable conditions, inclusive of an increase in raw material cost. To date, we have been able to manage these conditions without significant disruption to our business.

While we work closely with our suppliers, no assurance can be given that these efforts will be successful, and there may be events that cause supply interruption, reduction or termination that adversely impact our ability to manufacture and sell certain products. See further discussion of the risks related to the supply chain and raw materials in Item 1A. Risk Factors.

Our intellectual property, including patents, patent applications, trademarks, copyrights, know-how and trade secrets, is important to our business. We own or license intellectual property rights, including know-how and issued patents and pending patent applications in the U.S. and in other countries, which relate to various aspects of our business. In 2024, more than 170 utility and design patents were issued to West across the globe. Certain key value-added and proprietary products and processes are exclusively licensed from Daikyo. We believe, however, that neither our business nor any business segment is wholly dependent on a single intellectual property asset, license, or technology, by itself.

Our business activities are global and are subject to various federal, state, local, and foreign laws, rules, and regulations to healthcare, environmental protection, occupational health and safety, anti-corruption, export control, product safety and efficacy, employment, privacy and other areas. The design, development, manufacturing, marketing and labeling of certain of our products and our customers’ products that incorporate our products are subject to regulation by governmental authorities in the U.S., Europe and other countries, including the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency and the National Medical Products Administration (China). Regulatory authorities, including regulatory review and oversight, can impact the time and cost associated with the development and continued availability of our products, and they have the authority to take various administrative and legal actions against West. Compliance with existing and forthcoming laws and regulations can be costly and time consuming, and may require changes to our information technologies, systems and practices.

Changes in tax policy or trade regulations, or the imposition of new tariffs on imported products, could have an adverse effect on our business and results of operations. Compliance with these laws, rules and regulations did not require material capital expenditures in 2024 and is not expected to have a material effect on our capital expenditures, results of operations and competitive position in 2025 as compared to prior periods. For more information on the potential impacts of government regulations affecting our business, see "Item 1A. Risk Factors." There were no required material capital expenditures for adherence to our government-led regulatory standards in our facilities in 2024 outside the normal course of business, and there are currently no needed or planned material expenditures for 2025.

West is also subject to various federal and state laws, and laws outside the United States, concerning fraud and abuse, global anti-corruption, and export control. Many of the agencies enforcing these laws have increased their enforcement actions with respect to healthcare manufacturers in recent years. We remain committed as a company to comply with all laws and regulations applicable to our business.

Environmental Regulations

We are subject to various national, state and local provisions regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. Our compliance with these laws and regulations has not had a material impact on our financial position, results of operations or cash flows. There were no required material capital expenditures for environmental controls in our facilities in 2024 and there are currently no needed or planned material expenditures for 2025.

Our Proprietary Products customers primarily include many of the major biologic, generic, and pharmaceutical drug companies in the world, which incorporate our components and other offerings into their injectable products for distribution to the point of care and ultimate end-user, the patient. Our Contract-Manufactured Products customers include many of the world’s largest pharmaceutical, diagnostic, and medical device companies. Contract-Manufactured Products components generally are incorporated into our customers’ manufacturing lines for further processing or assembly. Our products and services are sold and distributed primarily through our own sales force and distribution network, with limited use of contract sales agents and regional distributors.

Our ten largest customers accounted for 43.4% of our consolidated net sales in 2024, and one of these customers, individually accounted for more than 10% of consolidated net sales, at 12.3% or $356.4 million, contributing to net sales in both the Proprietary and Contract Manufacturing reporting segments. Please refer to Note 3, Revenue, and Note 19, Segment Information, for additional information on our consolidated net sales.

With our range of proprietary technologies, we compete with several companies across our Proprietary Products product lines. Competition for these components is based primarily on product design and performance, quality, regulatory compliance, and scientific expertise, along with total cost.

In addition, there are a number of competitors supplying medical devices and medical device components, including a number of pharmaceutical manufacturers who are also potential customers of our medical devices and components. We compete in this market on the basis of our reputation for quality and reliability in engineering and project management, as well as our knowledge of, and experience in, compliance with regulatory requirements.

We have specialized knowledge of container closure components, which is integral to developing delivery systems. With our range of proprietary technologies, we compete with new and established companies in the area of drug delivery devices, including suppliers of prefillable syringes, auto-injectors, safety needles, and other proprietary systems.

We seek to differentiate ourselves from our competition by serving as a global supplier of integrated drug containment and delivery systems that can provide pre-approval primary packaging support and engineering development, analytical lab services and integrated solutions, regulatory expertise, and after-sale technical support. Customers also appreciate the global scope of our manufacturing capability and our ability to produce many products at multiple sites.

Our Contract-Manufactured Products business operates in very competitive markets for its products. The competition varies from smaller regional companies to large global assembly manufacturers. Given the cost pressures they face, many of our customers look to reduce costs by sourcing from low-cost locations. We seek to differentiate ourselves by leveraging our global capabilities and reputation and by employing new technologies such as high-speed automated assembly, insert-molding, multi-shot precision molding, and expertise with multiple-piece closure systems.

We maintain our own research-scale production facilities and laboratories for developing new products and offer contract engineering design and development services to assist customers with new product development. Our quality control, regulatory and laboratory testing capabilities are used to ensure compliance with applicable manufacturing and regulatory standards for primary and secondary pharmaceutical packaging components and drug delivery systems. Technological advances and scientific discoveries have accelerated the pace of change in primary packaging, drug delivery and administration technologies.

Commercial development of our new products and services for medical and pharmaceutical applications commonly requires several years. New products that we develop may require separate approval as medical devices, and products that are intended to be used in the packaging and delivery of pharmaceutical products are subject to both customer acceptance of our products and regulatory approval of the customer’s products following our development period.

We continue to pursue strategic initiatives in drug containment components, integrated drug containment systems, novel drug delivery devices, novel therapeutic experiences and administration systems.

We also continue to seek new innovative opportunities for acquisition, licensing, partnering or development of products, services and technologies.

Human Capital Management

As of December 31, 2024, we employed approximately 10,600 people, excluding contractors and temporary workers, in our operations throughout the world. During 2024, West hired approximately 1,800 new team members and experienced an attrition rate of approximately 17%. The following table presents the approximate percentage of our employees by region:

As of December 31, 2024, the following table presents the approximate percentage of our employees by business unit:

As of December 31, 2024, we had the following global gender demographics:

We strongly encourage our team members to engage in continuous learning and provide development opportunities to strengthen individual skills and gain new experiences with the goal to build talent from within. We offer resources such as our tuition reimbursement program and our online learning catalog, with more than 46,000 courses available. We centrally manage and organize on-the-job training, instructor-led trainings and online trainings in many different languages and topics through our global Learning Management System.

Our team members live our values (Passion for Customer, Leadership in Quality and One West Team) as they work together to support our mission to improve patients' lives. West’s Code of Conduct, available in multiple languages on westpharma.com, provides guidance to our team members on appropriate and ethical conduct. Every team member is required to undergo Code of Conduct and mutual respect in the workplace training annually.

Our focus on talent acquisition, performance management, resource planning and leadership assessment are strongly aligned with our inclusion, collaboration, and innovation strategies, all of which lead to more opportunities, better access to talent and stronger business performance.

West is committed to providing fair and competitive compensation and benefits programs to attract, retain and reward high-performing team members at all levels. We offer a comprehensive total rewards program to support the health, financial and home-life needs of our team members. Total Rewards at West are defined as the value of the Compensation and Benefits programs offered to employees, which aim to reflect the value of the job and the contribution of the individual, while linking employees’ performance to business and personal results. Based on country of employment, West may provide health care and retirement savings programs as well as paid time off, flexible work schedules, a Global Employee Assistance Program and an Employee Stock Purchase Program.

The health and safety of our team members has always been both a top priority and a cultural value. West's commitment to the safety of our teams starts at the top and is driven throughout our business by every level of management and by every team member across the globe. West has a Health, Safety, and Environment ("HSE") Governance Council consisting of West Leadership Team members and executive operations leaders to monitor and support our HSE process. West’s global HSE team is also a critical component in leading the safety efforts at our sites. Each manufacturing location has dedicated and trained HSE professionals, responsible for general safety oversight and regulatory compliance at the site. Through our SEE-DO-SAY program, we train, empower, and expect our team members to proactively identify and mitigate risk before an incident occurs. Our HSE and employee well-being can also be seen in our focus on quality implementation of proactive Leading Indicator programs and metrics, and team-member-led Hazard Identification programs that help to drive improved Lagging Indicator performance.

West has been committed to ESG topics for many years. During 2024, we continued to increase internal and external awareness of our ESG commitment by expanding our education and communication regarding our ESG program and initiatives and more closely integrating ESG considerations into our business processes. Our ESG program includes a senior-level cross-functional ESG team which has been working with executive leadership, our board and other stakeholders to enhance our ESG framework and ensure alignment with our corporate mission, vision and values. Going forward, the ESG program will have an increased focus on compliance, given the increased regulatory requirements, as well as advancing our long-term strategic priorities. Our long-term strategic priorities include focus on talent attraction, retention and engagement; a climate and greenhouse gas ("GHG") reduction strategy that incorporates renewable energy and reduced absolute and intensity emissions; developing a more sustainable and responsible supply chain; research and development that focuses on issues of sustainability including secondary packaging, beneficial reuse and recyclability; and, reduction of waste and water in our operational processes. These areas of focus are in addition to our commitments to safety, quality, business continuity, as well as business compliance and integrity. Additionally, our philanthropic programs are an essential element of our corporate citizenship especially as we focus on the areas of children’s health; access to healthcare; and science, technology, engineering and math education. We are also expanding our philanthropic scope to include more sustainability related initiatives. We solicit input from a variety of stakeholders including employees, customers, and suppliers on ways to improve in these and other ESG areas and see continued progress in these areas as critical to maintaining an engaged and responsible workforce.

We maintain a website at www.westpharma.com. Our Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) are available on our website under the Investors - Financial caption as soon as reasonably practical after we electronically file the material with, or furnish it to, the U.S. Securities and Exchange Commission (“SEC”). These filings are also available to the public over the Internet at the SEC’s website, www.sec.gov.

In Part III of this Form 10-K, we incorporate by reference certain information from parts of other documents filed with the SEC and from our Proxy Statement for the 2025 Annual Meeting of Shareholders (“2025 Proxy Statement”), which will be filed with the SEC within 120 days following the end of our 2024 fiscal year. Our 2025 Proxy Statement will be available on our website under the caption Investors - Financial - Annual Reports & Proxy when complete.

Information about our corporate governance, including our Corporate Governance Principles and Code of Conduct, as well as information about our Directors, Board Committees, Committee Charters, and instructions on how to contact the Board, is available on our website under the Investors - Corporate Governance heading. We intend to make any required disclosures regarding any amendments of our Code of Conduct under the caption Investors - Corporate Governance on our website. Information relating to the West Pharmaceutical Services Dividend Reinvestment Plan is also available on our website under the Investors - Transfer Agent caption.

Information on our website does not constitute part of this document.

We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, West Pharmaceutical Services, Inc., 530 Herman O. West Drive, Exton, PA 19341.

Investing in our common stock involves a high degree of risk. You should consider and carefully read all of the risks and uncertainties described below, as well as other information included in this Annual Report and in our other public filings. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition or results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your original investment. This Form 10-K also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.

General global economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession, may result in unfavorable conditions. Those conditions could negatively affect demand for our products due to customers decreasing their inventories in the near-term or long-term, reduction in sales due to raw material shortages, reduction in research and development efforts, our inability to sufficiently hedge our currency and raw material costs, insolvency of suppliers or customers, and exacerbate some of the other risks that affect our business, financial condition and results of operations.

Our systems and networks, as well as those of our customers, suppliers, service providers, and banks, have and may in the future become the target of cyberattacks or information security breaches which, in turn, could result in the unauthorized release and misuse of confidential or proprietary information about our company, our employees or our customers, as well as disrupt our operations or damage our facilities or those of third parties. Additionally, our systems are subject to regulation to preserve the privacy of certain data held on those systems. We maintain an extensive network of technical security controls, policy enforcement mechanisms and monitoring systems, in order to address these threats. While these measures are designed to prevent, detect and respond to unauthorized activity in our systems, certain types of attacks could result in financial or information losses and/or reputational harm. If we cannot comply with regulations or prevent the unauthorized access, release and/or corruption of our or our customers’ confidential, classified or personally identifiable information, our reputation could be damaged, and/or we could face financial losses.

We may also be required to incur additional costs to modify or enhance our systems, or to try to prevent or remediate any such attacks. Modifying or enhancing our systems may result in unanticipated or prolonged disruption events, which could have a material adverse effect on our business and/or results of operations.

A significant portion of our net sales and earnings are generated internationally. Sales outside of the U.S. accounted for 57.5% of our consolidated net sales in 2024 and we anticipate that sales from international operations will continue to represent a significant portion of our net sales in the future. In addition, many of our manufacturing facilities and suppliers are located outside of the U.S. and we intend to continue our expansion into emerging and/or faster-growing international markets. Our foreign operations subject us to certain commercial, political and financial risks. Our business in these foreign markets is subject to general political conditions, including any political instability (such as those resulting from war, terrorism and insurrections) and general economic conditions in these markets, such as inflation, deflation, interest rate volatility and credit availability. Additionally, a number of factors, including U.S. relations with the governments of the foreign countries in which we operate, changes to international trade agreements and treaties, increases in trade protectionism, or the weakening or loss of certain intellectual property protection rights in some countries, may affect our business, financial condition and results of operations. Foreign regulatory requirements, including those related to the testing, authorization, and labeling of products and import or export licensing requirements, could affect the availability of our products in these markets.

In addition to risks associated with general political conditions, our international operations are subject to fluctuations in foreign currency exchange rates. The functional currency for most of our foreign operations is the applicable local currency. As a result, fluctuations in foreign currency exchange rates affect the results of our operations and the value of our foreign assets and liabilities, which in turn may adversely affect results of operations and cash flows and the comparability of period-to-period results of operations. Foreign governmental policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Given the unpredictability and volatility of foreign currency exchange rates, ongoing or unusual volatility may adversely impact our business and financial conditions.

In order to reduce our exposure to fluctuations in foreign currency exchange rates, we have entered, and expect to continue to enter, into hedging arrangements, including the use of financial derivatives. There can be no certainty that we will be able to enter into or maintain hedges of these currency risks, or that our hedges will be effective, which could have a significant effect on our financial condition and operating results.

In addition, our international operations are governed by the U.S. Foreign Corrupt Practices Act and similar foreign anti-corruption laws. Global enforcement of anti-corruption laws has increased substantially in recent years, with more enforcement proceedings by U.S. and foreign governmental agencies and the imposition of significant fines and penalties. While we have implemented policies and procedures relating to compliance with these laws, our international operations create the risk that there may be unauthorized payments or offers of payments made by employees, consultants, sales agents or distributors. Any alleged or actual violations of these laws may subject us to government investigations and significant criminal or civil sanctions and other liabilities, and negatively affect our reputation.

A substantial majority of our outstanding trade receivables are not covered by collateral or credit insurance. In addition, we have made prepayments and other advances in the normal course of business. While we have procedures to monitor and limit exposure to credit risk on trade receivables and other current assets, there can be no assurance such procedures will effectively limit our credit risk and avoid losses, which could have a material adverse effect on our financial condition and operating results.

Potential future disruptions in access to bank deposits or lending commitments due to bank failure could materially and adversely affect our liquidity, our business and financial condition. Even with our continued effort to mitigate counterparty risk by working with highly liquid, well capitalized counterparties, the failure of any bank in which we deposit our funds could reduce the amount of cash we have available for our operations or delay our ability to access such funds. Any such failure may increase the possibility of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions. In the event we have a commercial relationship with a bank that has failed or is otherwise distressed, we may experience delays or other issues in meeting our financial obligations. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our cash and cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition.

Our business depends to a substantial extent on customers’ continued sales and development of products that are delivered by injection. If (i) our customers fail to continue to sell, develop and deploy injectable products; (ii) our customers reconfigure their drug product or develop new drug products requiring less frequent dosing; or (iii) we are unable to develop new products that assist in the delivery of drugs by alternative methods, our sales and profitability may suffer.

We compete with several companies across our major product lines. Because of the special nature of these products, competition is based primarily on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost-control programs across their operations.

Companies often compete on the basis of price. We aim to differentiate ourselves from our competition by being a “full-service, value-added” global supplier that is able to provide pre-sale compatibility studies, engineering support, and other services and sophisticated post-sale technical support on a global basis. However, we face continued pricing pressure from our customers and competitors. If we are unable to resist or offset the effects of continued pricing pressure through our value-added services, improved operating efficiencies and reduced expenditures, or if we have to reduce our prices, our sales and profitability may suffer.

The pharmaceutical and healthcare industries continue to experience a significant amount of consolidation. As a result of this consolidation, competition to provide goods and services to customers has increased. In addition, group purchasing organizations and integrated health delivery networks have served to concentrate purchasing decisions for some customers, which has placed pricing pressure on suppliers. Further consolidation within the industries we serve could exert additional pressure on the prices of our products.

The medical technology industry is subject to rapid technological changes, and we face significant competition across our product lines and in each market in which our products are sold. We face this competition from a wide range of companies, including large medical device companies, some of which have greater financial and marketing resources than we do. We also face competition from firms that are more specialized than we are with respect to particular markets. In some instances, competitors, including pharmaceutical companies, also offer, or are attempting to develop, alternative therapies for diseases that may be delivered via their own, or without, a medical device. The development of new or improved products, processes or technologies by other companies (such as needle-free injection technology) may reduce customer demand for our products or render some of our products or proposed products obsolete or less competitive. In addition, any failure or inability to meet increased customer quality expectations could cause a reduction in demand.

We have manufacturing sites throughout the world. In some instances, however, the manufacturing of certain product lines is concentrated in one or only a few of our plants. The functioning of our manufacturing and distribution assets and systems could be disrupted for reasons either within or beyond our control, including, without limitation: extreme weather, water scarcity and other longer-term climatic changes; natural or man-made disasters; pandemic; war; accidental damage; disruption to the supply of material or services; product quality and safety issues; power outages; systems failure; workforce actions; or environmental matters. There is a risk that incident management systems in place may prove inadequate and that any disruption may materially adversely affect our ability to make and sell products and therefore, materially adversely affect our reputation, performance or financial condition.

We conduct business in most of the major pharmaceutical markets in the world. Our international operations and our ability to implement our overall business strategy (including our plan to continue expanding into emerging and/or faster-growing markets outside of the U.S.) are subject to risks and uncertainties that can vary by country, and include: transportation delays and interruptions; political and economic instability and disruptions; imposition of duties and tariffs; import and export controls; the risks of divergent business expectations or cultural incompatibility inherent in establishing and maintaining operations in foreign countries; difficulties in staffing and managing multi-national operations; labor strikes and/or disputes; and potentially adverse tax consequences. Limitations on our ability to enforce legal rights and remedies with third parties or our joint venture partners outside of the U.S. could also create exposure. In addition, we may not be able to operate in compliance with foreign laws and regulations, or comply with applicable customs, currency exchange control regulations, transfer pricing regulations or any other laws or regulations to which we may be subject, in the event that these laws or regulations change. Any of these events could have an adverse effect on our international operations in the future by reducing the demand for our products or decreasing the prices at which we can sell our products, or otherwise have an adverse effect on our financial condition, results of operations and cash flows.

We generally purchase our raw materials and supplies required for the production of our products in the open market. For reasons of quality assurance, sole source availability or cost effectiveness, many components and raw materials are available and/or purchased only from a single supplier. Due to the stringent regulations and requirements of the FDA and other regulatory authorities regarding the manufacture of our products and the availability of such raw materials, we may not be able to quickly establish additional or replacement sources for these components or raw materials or do so without excessive cost. As a result, a reduction or interruption in supply, or an inability to secure alternative sources of raw materials or components, could have a material adverse effect on our business and/or results of operations.

We use three basic raw materials in the manufacture of our products: elastomers (which include synthetic and natural material), aluminum and plastic. In addition, our manufacturing facilities consume a wide variety of energy products to fuel, heat and cool our operations. The price and supply of these materials and energy sources are cyclical and volatile and may be impacted or disrupted for reasons beyond our control, including supplier shutdowns, supplier capacity constraints, transportation delays, inflationary pricing pressures, work stoppages, labor shortages, geopolitical developments and governmental regulatory actions.

For example, the prices of certain commodities, particularly petroleum-based raw materials, have in the recent past exhibited rapid changes, affecting the cost of synthetic elastomers and plastic. While we generally attempt to pass along increased costs to our customers in the form of sales price increases, historically there has been a time delay between raw material and/or energy price increases and our ability to increase the prices of our products. In some circumstances, we may not be able to increase the prices of our products due to competitive pressure and other factors. If we are unable to pass along increased raw material prices and energy costs to our customers, our profitability, and thus our financial condition, may be adversely affected.

Our growth partly depends on new-product innovation and the development and commercialization of proprietary multi-component systems for injectable drug administration and other healthcare applications. Product development and commercialization is inherently uncertain and is subject to a number of factors outside of our control, including any necessary regulatory approvals and commercial acceptance for the products. The ultimate timing and successful commercialization of new products and systems requires substantial evaluations of the functional, operational, clinical, and economic viability of our products. In addition, the timely and adequate availability of filling capacity is essential to both conducting definitive stability trials and the timing of commercialization of customers’ products in Crystal Zenith vials, syringes and cartridges. Delays, interruptions or failures in developing and commercializing new-product innovations or proprietary multi-component systems could adversely affect future revenues and operating income. In addition, adverse conditions may also result in future charges to recognize impairment in the carrying value of our goodwill and other intangible assets, which could have a material adverse effect on our financial results.

We expect to continue to seek acquisition opportunities that compliment and expand our existing operations. However, we may be unable to identify suitable targets, opportunistic or otherwise, for acquisitions or other strategic transactions in the future. If we identify a suitable candidate, our ability to successfully implement the strategic transaction would depend on a variety of factors, including our ability to obtain financing on acceptable terms and to comply with the restrictions contained in our debt agreements. Strategic transactions involve risks, including those associated with integrating the operations or maintaining the operations as separate (as applicable), financial reporting, disparate technologies, and personnel of acquired companies, joint ventures or related companies; managing geographically dispersed operations or other strategic investments; the diversion of management’s attention from other business concerns; the inherent risks in entering markets or lines of business in which we have either limited or no direct experience; the potential loss of key employees, customers and strategic partners of acquired companies, joint ventures or companies in which we may make strategic investments; and potentially other unknown risks. We may not successfully integrate any businesses or technologies we may acquire or strategically develop in the future and may not achieve anticipated revenue and cost benefits relating to any such strategic transactions. Strategic transactions may be expensive, time consuming and may strain our resources. Strategic transactions may not be accretive to our earnings and may negatively impact our results of operations as a result of, among other things, the incurrence of debt, one-time write-offs of goodwill, additional carrying costs of patent or trademark portfolios, and amortization expenses of other intangible assets. In addition, strategic transactions that we may pursue could result in dilutive issuances of equity securities.

The design, manufacturing and marketing of pharmaceutical packaging and medical devices involve certain inherent risks. Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks relating to the use of our products can lead to injury or other adverse events. These events could lead to recalls or safety alerts relating to our products (either voluntary or required by the FDA or similar governmental authorities in other countries), and could result, in certain cases, in the removal of a product from the market.

A recall could result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products. Personal injuries relating to the use of our products can also result in product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in new product approvals.

Our future success depends, in large part, on our ability to attract and retain key employees, including our executive officers and individuals in technical, marketing, sales, and research positions. Competition for experienced employees, particularly for persons with specialized skills, can be intense. Our ability to recruit such talent will depend on a number of factors, including compensation and benefits, work location and work environment. If we cannot effectively recruit and retain qualified executives and employees, our business could be adversely affected. Although we believe that we will be able to attract and retain talented personnel and replace key personnel should the need arise, our inability to do so on a timely basis could disrupt the operations of the unit affected or our overall operations. In addition, because of the complex nature of many of our products and programs, we are generally dependent on an educated and highly skilled engineering staff and workforce. Our operations could be disrupted by a shortage of available skilled employees.

We must adjust our production capacity in accordance with customer demand changes and remain focused on increasing capacity at various facilities through our capital strategy. If we are unable to increase capacity levels at the rate we expect, or if unforeseen costs or other challenges associated with increasing that capacity arise, we may not be able to achieve our financial targets.

Additionally, we are committed to supporting a full portfolio of our products for our customers. That commitment, along with shifts of product mix and complexity, may result in more frequent equipment change-overs and potentially increased costs because of the high fixed cost nature of our business, causing lower gross margins due to under-absorption of those fixed costs.

Our results of operations and earnings may not meet guidance or expectations.

We provide public guidance on our expected results of operations for future periods. This guidance is comprised of forward-looking statements subject to risks and uncertainties, including the risks and uncertainties described in this Form 10-K and in our other public filings and public statements, and is based on assumptions we make at the time we provide such guidance. Our guidance may not always be accurate. If, in the future, our results of operations for a particular period do not meet our guidance or the expectations of investment analysts, or if we reduce our guidance for future periods, the market price of our common stock could decline significantly.

We have historically paid dividends. However, there can be no assurance that we will pay or declare dividends in the future. The actual declaration and payment of future dividends, the amount of any such dividends, and the establishment of record and payment dates, if any, are subject to determination by our Board of Directors each quarter after its review of our then-current strategy, applicable debt covenants and financial performance and position, among other things. Our declaration and payment of future dividends is subject to risks and uncertainties, including deterioration of our financial condition or position; inability to declare a dividend in compliance with applicable laws or debt covenants; an increase in our cash needs or decrease in available cash; and the business judgment of the Board of Directors that a declaration of a dividend is not in our best interest.

Key value-added and proprietary products and processes are licensed from our affiliate, Daikyo, including but not limited to, Crystal Zenith, FluroTec® and B2-coating technologies. Our rights to these products and processes are licensed pursuant to agreements that expire in 2027. However, if the agreements are terminated early or not renewed, our business could be adversely impacted.

As a multinational corporation with operations and distribution channels throughout the world, we are subject to and must comply with extensive laws and regulations in the United States and other jurisdictions in which we have operations and distribution channels. For example, the design, development, manufacturing, marketing and labeling of certain of our products and our customers’ products that incorporate our products are subject to regulation by governmental authorities in the U.S., Europe and other countries, including the FDA, the European Medicines Agency and the National Medical Products Administration (China). Complying with governmental regulation can be costly and can result in required modification or withdrawal of existing products and a substantial delay in the introduction of new products. Failure to comply with applicable regulatory requirements or failure to obtain regulatory approval for a new product could subject us to fines, sanctions or other penalties that could negatively affect our reputation, business, financial condition, and results of operations.

The global nature of our business also means legal and compliance risks, such as anti-bribery, anti-corruption, fraud, trade, environmental, competition, privacy, and other regulatory matters, will continue to exist and additional legal proceedings and other contingencies will arise from time to time, which could adversely affect us. In addition, the adoption of new laws or regulations, or changes in the interpretation of existing laws or regulations, may result in significant unanticipated legal and reputational risks. Any current or future legal or regulatory proceedings could divert management's attention from our operations and result in substantial legal fees.

The process of obtaining and maintaining FDA and other required regulatory approvals is expensive and time-consuming. Historically, most medical devices that incorporate our technologies and medical devices that we produce have been subject to the FDA’s 510(k) marketing approval process, which typically lasts from six to nine months. Supplemental or full pre-market approval reviews require a significantly longer period, delaying commercialization. Changes in regulation on a global scale must be monitored and actions taken to ensure ongoing compliance. Pharmaceutical products that incorporate our technologies and medical devices that we produce are subject to the FDA’s New Drug Application process, which typically takes a number of years to complete. Additionally, biotechnology products that incorporate our technologies and medical devices that we produce are subject to the FDA’s Biologics License Application process, which also typically takes a number of years to complete. Outside of the U.S., sales of medical devices and pharmaceutical or biotechnology products are subject to international regulatory requirements that vary from country to country. The time required to obtain approval for sale internationally may be longer or shorter than that required for FDA approval. There is no certainty that any regulatory approval may be obtained or maintained indefinitely, and our ability to launch products to the market and maintain market presence is not guaranteed.

An effect of the governmental regulation of our medical devices and our customers’ drug products, devices, and manufacturing processes is that compliance with regulations makes it difficult to change components and devices produced by one supplier with those from another supplier, due to the large amount of data and information that customers must generate to demonstrate that the components and devices are equivalent and pose no additional risk to the patient. The regulation of our medical devices and our customers’ products that incorporate our components and devices has increased over time. If the applicable regulations were to be modified in a way that reduced the level of data and information needed to prove equivalency for a change from one supplier’s components or devices to those made by another, it is likely that the competitive pressure would increase and adversely affect our sales and profitability.

Our patents, trademarks and other intellectual property are important to our business. We rely on patent, trademark, copyright, trade secret, and other intellectual property laws, as well as nondisclosure and confidentiality agreements and other methods, to protect our proprietary products, information, technologies and processes. We also have obligations with respect to the non-use and non-disclosure of third-party intellectual property. We may need to engage in litigation or similar activities to enforce our intellectual property rights, to protect our trade secrets or to determine the validity and scope of proprietary rights of others. Any such litigation could require us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. There can be no assurance that the steps we will take to prevent misappropriation, infringement or other violation of our intellectual property or the intellectual property of others will be successful. In addition, effective patent, trademark, copyright, and trade secret protection may be unavailable or limited for some of our proprietary products in some countries. Failure to protect our intellectual property or successfully invalidate or defend against intellectual property protections of third parties could harm our business and results of operations. In addition, if relevant and effective patent protection is not available or has expired, we may not be able to prevent competitors from independently developing products and services similar or duplicative to ours.

We earn a substantial portion of our income in foreign countries and, as such, we are subject to the tax laws in the United States and numerous foreign jurisdictions. Current economic and political conditions make tax laws and regulations, or their interpretation and application, in any jurisdiction subject to significant change.

Proposals to reform U.S. and foreign tax laws could significantly impact how U.S. multinational corporations are taxed on foreign earnings and could increase the U.S. corporate tax rate. Although we cannot predict whether or in what form these proposals may pass, several of the proposals considered, if enacted into law, could have an adverse impact on our effective tax rate, income tax expense and cash flows.

We utilize tax rulings and other agreements to obtain certainty in treatment of certain tax matters. These rulings and agreements expire from time to time and may be extended when certain conditions are met or terminated if certain conditions are not met. The impact of any changes in conditions would be the loss of certainty in treatment thus potentially impacting our effective income tax rate.

We are also subject to the examination of our tax returns by the United States Internal Revenue Service (“IRS”) and other tax authorities. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of its provision for income taxes. Although we believe our tax provisions are adequate, the final determination of tax audits and any related disputes rapidly change and could be materially different from our historical income tax provisions and accruals. The results of audits or related disputes could have an adverse effect on our financial statements for the period or periods for which the applicable final determinations are made. For example, we and our subsidiaries are also engaged in a number of intercompany transactions across multiple tax jurisdictions. Although we believe we have clearly reflected the economics of these transactions and the proper local transfer pricing documentation is in place, tax authorities may propose and sustain adjustments that could result in changes that may impact our mix of earnings in countries with differing statutory tax rates.

In addition to our own sensitive and proprietary business information, we handle transactional and personal information worldwide. As a result, we must comply with increasingly complex and rigorous, and sometimes conflicting laws, regulatory standards, industry standards, external and internal privacy and security policies, contracts and other obligations that govern the processing of business and personal data by us and on our behalf. For example and not limited to, the European Union’s General Data Protection Regulation (the “EU GDPR”), the United Kingdom’s GDPR (the “UK GDPR”) and California’s Consumer Privacy Act of 2018 (the "CCPA"), as expanded by the California Privacy Rights Act of 2020 (“CPRA”), impose obligations on companies regarding the handling of personal data and provide certain individual privacy rights to persons whose data is stored. Furthermore, multiple states in the United States have enacted data privacy laws. Additionally, laws in certain jurisdictions require data localization and impose restrictions on the transfer of personal information across border. For example, the EU GDPR generally restricts the transfer of personal information to countries outside of the European Economic Area without appropriate safeguards or other measures. If we cannot implement a valid compliance mechanism for cross-border privacy and security transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal information from Europe or elsewhere.

Compliance with existing and forthcoming laws and regulations can be costly and time consuming, and may require changes to our information technologies, systems and practices and to those of any third parties that process personal information on our behalf. If we fail, or are perceived to have failed, to address or comply with obligations related to data privacy and security, we could face significant consequences, including, but not limited to, proceedings against the Company by governmental entities (e.g. investigations, fines, penalties, audits, inspections) or other entities or individuals, additional reporting requirements and/or governmental agency oversight, damage to our reputation and credibility, or inability to process data or operate in certain jurisdictions, any of which could have a negative impact on revenues and profits.

There is continuing concern from members of the scientific community and the general public that emissions of GHG and other activities have or will cause significant changes in weather patterns and increase the frequency or severity of extreme weather events, including droughts, hurricanes, wildfires and flooding. These types of extreme weather events have and may continue to adversely impact us, raw material availability, our suppliers, our customers and their ability to purchase our products and our ability to timely manufacture and transport our products.

We believe it is likely that the scientific and political attention to issues concerning the extent and causes of climate change will continue, with new and more restrictive legislation or regulations and focus on ESG initiatives that could affect our financial condition, results of operations and cash flows. Foreign, federal, state and local regulatory and legislative bodies, such as the SEC, have proposed various legislative and regulatory measures relating to increased transparency and standardization of reporting related to factors that may include climate change, regulating GHG emissions, energy policies, recycling of plastic materials, waste taxes, and other governmental charges and mandates. If additional legislation or regulations were enacted, we could incur increased energy, environmental, administrative and other costs and capital expenditures to comply with the limitations.

Failure to comply with these regulations could result in fines and could affect our business, financial condition, results of operations and cash flows. We could also face increased costs related to defending and resolving legal claims and other litigation related to climate change and any alleged impact of our operations on climate change.

We, along with other companies in many business sectors have been implementing and expanding ESG and sustainability strategies, specifically ways to track and reduce GHG emissions. As a result, our customers may request that changes be made to our products, procedures or facilities, as well as other aspects of our business, that increase costs and may require the investment of capital or reduction in profit margins if not offset by price increases, customer investment or other cost savings. Failure to provide climate-friendly products or demonstrate GHG reductions could potentially result in loss of market share. Additionally, the costs of procuring energy, including renewable energy, or offsetting GHG emissions to meet our goals, satisfy government regulations or meet the requests of our customers may increase.

We are subject to the Foreign Corrupt Practices Act (the "FCPA"), the U.K. Bribery Act and other anti-bribery, anti-corruption, and anti-money laundering laws in various jurisdictions around the world. The FCPA, the U.K. Bribery Act and similar applicable laws generally prohibit companies, as well as their officers, directors, employees and third-party intermediaries, business partners and agents, from making improper payments or providing other improper things of value to government officials or other persons. We and our third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state owned or affiliated entities and other third parties where we may be held liable for corrupt or other illegal activities, even if we do not explicitly authorize them. While we have policies and procedures and internal controls to address compliance with such laws, we cannot provide assurance that all of our employees and third-party intermediaries, business partners and agents will not take actions in violation of such policies and laws, for which we may be ultimately held responsible. To the extent that we learn that any of our employees or third-party intermediaries, business partners or agents do not adhere to our policies, procedures, or internal controls, we are committed to taking appropriate remedial action. In the event that we believe or have reason to believe that our directors, officers, employees or third-party intermediaries, agents or business partners have or may have violated such laws, we may be required to investigate or to have outside counsel investigate the relevant facts and circumstances. Detecting, investigating and resolving actual or alleged violations can be extensive and require a significant diversion of time, resources, and attention from senior management. Any violation of the FCPA, the U.K. Bribery Act or other applicable anti-bribery, anti-corruption and anti-money laundering laws could result in whistleblower complaints, adverse media coverage, investigations, loss of export privileges, and criminal or civil sanctions, penalties, and fines, any of which may adversely affect our business and financial condition.

The manufacturing of some of our products has involved, and may continue to involve, the use, transportation, storage, and disposal of hazardous or toxic materials and is subject to various environmental protection and occupational health and safety laws and regulations in the countries in which we operate. This has exposed us in the past, and could expose us in the future, to risks of accidental contamination and events of non-compliance with environmental laws. Any such occurrences could result in regulatory enforcement or personal injury and property damage claims or could lead to a shutdown of some of our operations, which could have an adverse effect on our business and results of operations. We currently incur costs to comply with environmental laws and regulations and these costs may become more significant, especially as the laws become more stringent and our use of materials changes.

Our sales depend, in part, on the extent to which healthcare providers and facilities are reimbursed by government authorities (including Medicare, Medicaid and comparable foreign programs) and private insurers for the costs of our products. The coverage policies and reimbursement levels of third-party payers, which can vary among public and private sources and by country, may affect which products customers purchase and the prices they are willing to pay for those products in a particular jurisdiction. Reimbursement rates can also affect the market acceptance rate of new technologies and products. Reforms to reimbursement systems in the U.S. or abroad, changes in coverage by private payers, or adverse decisions by payers could significantly reduce reimbursement for procedures using our products, which could adversely affect customer demand or the price customers are willing to pay for such products.

Initiatives to limit the growth of healthcare costs in the U.S. and other countries where we do business may also put industry-wide pressure on medical device or clinical diagnostic pricing. In the U.S., these include, among others, value-based purchasing and managed care arrangements. Governments in other countries are also using various mechanisms to control healthcare expenditures, including increased use of competitive bidding and tenders as well as price regulation.

Stock markets in general and our common stock in particular have experienced significant price and trading volume volatility over recent years. The market price and trading volume of our common stock may continue to be subject to significant fluctuations due to factors described under this Item 1A. Risk Factors, as well as economic and geopolitical conditions in general and to variability in the prevailing sentiment regarding our operations or business prospects, as well as, among other things, changing investment priorities of our shareholders.

As of the filing of this Form 10-K, there were no unresolved comments from the Staff of the SEC.

The Company has implemented the Committee of Sponsoring Organizations (“COSO”) Enterprise Risk Management (“ERM”) Framework, which outlines the process by which an organization can view any risk by way of governance and culture, integration into strategy, risk assessments, reviewing capabilities and practices, and monitoring and reporting. This process would apply to the cybersecurity risk as it would any of the other enterprise risks. We follow the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“CSF”) with layered security controls to help identify, protect against, detect, respond to, and recover from cyber-attacks. To safeguard our information assets, we have put various procedures and technologies in place. For example, our Cybersecurity Incident Response Plan clearly defines roles and responsibilities for the investigation of and response to information security incidents to minimize disruption of critical computing services and operations and prevent the loss or theft of sensitive or mission-critical information. Our plan covers various cyber incidents like ransomware attacks, cyber-intrusions, data loss, denial of service, insider threats, malware attacks, and others. In a material cybersecurity incident, our D&T team, inclusive of our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, address the threat via established escalation procedures, roles, responsibilities, and communication. Any cybersecurity incident that is declared as a crisis would follow our global Incident and Crisis Response and Management Procedure, which includes escalation to the West Leadership Team and Board of Directors, as deemed necessary pending the materiality of the incident. We have not encountered cybersecurity challenges that have materially impacted our operations or financial condition. In addition, we retain an external cybersecurity consultancy company to assist when a cybersecurity event arises, as needed and, in addition we maintain appropriate cybersecurity liability insurance.

The Company also educates and shares best practices globally with its employees to raise awareness of cybersecurity threats. As part of our onboarding process, we train all new employees on cybersecurity and conduct an annual retraining of all employees on cybersecurity standards. Training also includes how to recognize, report and properly respond to phishing and social engineering schemes. Multiple phishing simulation exercises are conducted throughout the year to increase cybersecurity awareness. Our cybersecurity defenses also utilize technologies such as next generation firewalls, Zero Trust architecture, intrusion detection and prevention measures, anti-malware software, advance threat protection, multifactor authentication, network segmentation and encryption to ensure the security of West intellectual properties, customer and vendor data. In addition, we have a dedicated 24-by-7 Security Operations Center to facilitate the monitoring of the Company's cybersecurity landscape and associated applications.

Our approach to cybersecurity begins with our responsibility for strong governance and controls. Security begins at the top of our organization, where Company leadership consistently communicates the requirements for vigilance and compliance throughout the organization, and then leads by example. Our diligence and assessment extend beyond West, as the Company performs a cybersecurity assessment when third-party vendors and service providers are onboarded. Throughout the year, we monitor the effectiveness of our third-party vendors' and service providers' control environment, assessing any impact to our Company. The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, who provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Additionally, our ERM program enables a portfolio view of the risks inherent in our business, including cybersecurity. The ERM function monitors and reports on these top risks with periodic updates to the Audit Committee and our Board of Directors, annual updates to the Board of Directors, and regular reporting to the West Leadership Team on risk mitigation and response efforts. Security controls and processes are developed and maintained to protect sensitive and confidential information while ensuring availability and integrity.

Our corporate headquarters are located at 530 Herman O. West Drive, Exton, Pennsylvania 19341.

The following table summarizes our facilities by segment and geographic region. All facilities shown are owned except where otherwise noted.

(1)This manufacturing facility is also used for research and development activities.

(2)This facility is leased in whole or in part.

Our Proprietary Products reportable segment leases facilities located in Scottsdale, AZ, Radnor, PA, Germany, and Israel for research and development, as well as other activities. Sales offices in various locations are leased under contractual arrangements.

None.

The executive officers of the Company are set forth in this table. Generally, executive officers are elected by the Board of Directors annually at the regular meeting of the Board of Directors following the Annual Meeting of Shareholders. Additionally, executive officers may be elected upon hire or due to a promotion.

Our common stock is listed on the New York Stock Exchange (“NYSE”) under the symbol “WST.” As of February 6, 2025, we had 523 shareholders of record, which excludes beneficial owners whose shares were held by brokerage firms, depositaries and other institutional firms in “street names” for their customers.

We paid a quarterly dividend of $0.19 per share on our common stock in each of the first three quarters of 2023; $0.20 per share in the fourth quarter of 2023 and each of the first three quarters of 2024; and $0.21 per share in the fourth quarter of 2024. We will continue to review our ability to pay cash dividends on an ongoing basis and dividends may be declared at the discretion of our Board of Directors. When considering whether to declare a dividend, our Board of Directors will take into account:

•general economic and business conditions;

•our financial condition and operating results;

•our available cash and current and anticipated cash needs;

•our capital requirements;

•contractual, legal, tax and regulatory restrictions on the payment of dividends by us; and

•such other factors as our Board of Directors may deem relevant.

The following table shows information with respect to purchases of our common stock made during the three months ended December 31, 2024 by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act:

(1) In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. During the three months ended December 31, 2024, we purchased 173,246 shares of our common stock under the program at a cost of $54.4 million, or an average price of $314.06 per share. During the year ended December 31, 2024, we purchased 1,583,032 shares of our common stock under the program at a cost of $560.9 million, or an average price of $354.30 per share.

The following performance graph compares the cumulative total return to holders of our common stock with the cumulative total return of the Standard & Poor’s 500 Index (“S&P 500”) and the Standard & Poor's 500 Health Care Index, for the five years ended December 31, 2024. The performance graph is based on historical data and is not indicative of, or intended to forecast, future performance of our common stock.

Cumulative total return to shareholders is measured by dividing total dividends (assuming dividend reinvestment) plus the per-share price change for the period by the share price at the beginning of the period. The cumulative shareholder return on our common stock is based on an investment of $100 on December 31, 2019 and is compared to the cumulative total return of the S&P indices mentioned above over the period with a like amount invested.

*Five year total return data obtained from NASDAQ IR Insight The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of the Company.

It should be read in conjunction with our consolidated financial statements and the accompanying footnotes included in Part II, Item 8 of this Form 10-K. These historical financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of this Form 10-K.

For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to adjusted consolidated operating profit and adjusted consolidated operating profit margin, which exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically-identified income or expense items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and excluding the effects of unallocated items are not in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.

Our business operations are organized into two global segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.

We have operations based in Israel that conduct research and development activities and manufacture certain components for our devices. Our Israel-based facilities continue to substantially operate as they had prior to the conflict in Israel and surrounding area. We continue to monitor the impact of the conflict in Israel and surrounding areas on our operations and those of our suppliers, the possible expansion of such conflict and potential geopolitical consequences, if any, on our business and operations.

In assessing the performance of our business, we consider a variety of performance and financial measures. We believe the items discussed below provide insight into the factors that affect these key measures.

Our net sales result from the sale of goods or services and reflect the net consideration which we expect to receive in exchange for those goods or services.

Several factors affect our reported net sales in any period, including product, payer and geographic sales mix, operational effectiveness, pricing realization, timing of orders and shipments, regulatory actions, competition, and business acquisitions that involve our customers or competitors.

Cost of goods and services sold includes personnel costs, manufacturing costs, raw materials and product costs, freight costs, depreciation, and facility costs associated with our manufacturing and warehouse facilities. Fluctuations in our cost of goods sold correspond with the fluctuations in sales units as well as inflationary and other market factors that influence our cost base.

Gross profit is calculated as net sales less cost of goods and services sold. Our gross profit is affected by product and geographic sales mix, realized pricing of our products, the efficiency of our manufacturing operations and the costs of materials used to make our products.

Research and development expenses relate to our investments in improvements to our manufacturing processes, product enhancements, and additional investments in our elastomeric packaging components, formulation development, integrated drug containment systems, self-injection systems and drug administration consumables.

We expense research and development costs as incurred. Our research and development expenses fluctuate from period to period primarily based on the ongoing improvements to our manufacturing processes and product enhancements.

Selling, general and administrative expenses primarily include personnel costs, incentive compensation, insurance, professional fees, and depreciation.

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures:

During 2024, we recorded a tax benefit of $19.5 million associated with stock-based compensation.

During 2023, we recorded a tax benefit of $32.0 million associated with stock-based compensation.

During 2022, we recorded a tax benefit of $16.5 million associated with stock-based compensation.

(1)During 2024, the Company recorded expense to restructuring and other charges of $2.1 million. The net expense represents the impact of two items, the first of which is $4.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within cost of goods and services sold. During 2022, the Company recorded expense to restructuring and other charges of $23.8 million, which primarily included a charge of $8.7 million in net severance and post-employment benefits primarily in connection with our plan to adjust our operating cost base and $15.3 million in asset-related charges associated with this plan.

(2)During 2024, 2023 and 2022, the Company recorded $0.8 million, $0.7 million and $0.7 million, respectively, of amortization expense within operating profit associated with an acquisition of an intangible asset during the second quarter of 2020. Additionally, during 2024, 2023 and 2022, the company recorded $2.1 million of amortization expense in association with an acquisition of increased ownership interest in Daikyo.

(3)During 2023, the Company recorded expense of $11.6 million as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(4)During 2023 and 2022, the Company recorded cost investment impairment charges of $4.3 million and $3.5 million, respectively.

(5)During 2023, the Company recorded a benefit of $3.8 million within other nonoperating expense (income) as a result of a favorable legal settlement related to a matter not included in our normal operations.

(6)During 2022, we recorded a gross pension settlement charge of $52.2 million within other nonoperating expense (income), which primarily relates to the full settlement of the U.S. qualified defined benefit plan (the "U.S. pension plan"). Please refer to Note 15, Benefit Plans, for further discussion of these items.

(7)During 2022, the Company increased its expected tax benefit related to the prepayment of future royalties from one of its subsidiaries by $1.3 million.

(8)During 2022, the Company incurred additional tax expense of $5.7 million due to the impact of a tax law change in the state of Pennsylvania enacted during the period.

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures. Discussion of the year-over-year changes for the fiscal year ended December 31, 2023 compared to the fiscal year ended December 31, 2022 and the results of operations and cash flows for the fiscal year ended December 31, 2022 is included in Item 7, Management’s Discussion and Analysis of Financial Condition and Result of Operations of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 20, 2024, and is incorporated herein by reference.

Percentages in the following tables and throughout this Results of Operations section may reflect rounding adjustments.

The following table presents net sales, consolidated and by reportable segment:

Consolidated net sales decreased by $56.6 million, or 1.9%, in 2024, including an unfavorable foreign currency translation impact of $7.0 million. Excluding foreign currency translation effects and the impact related to the disposal of one of our plants of $4.3 million, consolidated net sales decreased by $45.3 million, or 1.5%.

Proprietary Products – Proprietary Products net sales decreased by $62.8 million, or 2.6%, in 2024, including an unfavorable foreign currency translation impact of $6.9 million. Excluding foreign currency translation effects and the impact related to the disposal of one of our plants of $4.3 million, net sales decreased by $51.6 million, or 2.2%, due to a decline in sales of certain High-Value Product ("HVP") offerings due to customer inventory management, primarily FluroTec® products, Westar® components and Daikyo® components. These reductions were partially offset by an increase in sales of self-injection device platforms and increased sales prices, which includes approximately $47 million in customer incentives earned in connection with volumes achieved during 2024, as compared to 2023.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $6.2 million, or 1.1%, in 2024, including an unfavorable foreign currency translation impact of $0.1 million. Excluding foreign currency translation effects, net sales increased by $6.3 million, or 1.1%, primarily due to an increase in sales of self-injection devices for obesity and diabetes and sales price increases, offset by a decrease in sales of healthcare diagnostic devices.

The following table presents gross profit and related gross margins, consolidated and by reportable segment and by unallocated:

Consolidated gross profit decreased by $130.7 million, or 11.6%, in 2024, including an unfavorable foreign currency translation impact of $2.1 million. Consolidated gross profit margin decreased by 3.8 margin points in 2024.

Proprietary Products – Proprietary Products gross profit decreased by $133.5 million, or 12.9%, in 2024, including an unfavorable foreign currency translation impact of $2.1 million. Proprietary Products gross profit margin decreased by 4.5 margin points in 2024. The decrease is driven by lower plant absorption from reduced customer demand and an unfavorable shift in mix of products sold from HVP Components to HVP Delivery Devices. These headwinds were partially offset by increased sales prices and approximately $47 million in customer incentives earned in connection with volumes achieved during 2024, as compared to 2023.

Contract-Manufactured Products – Contract-Manufactured Products gross profit increased by $2.0 million, or 2.1%, in 2024. Contract-Manufactured Products gross profit margin increased by 0.1 margin points in 2024, primarily due to increased sales prices.

The following table presents consolidated R&D costs:

Consolidated R&D costs increased by $0.7 million, or 1.0%, in 2024, as compared to 2023, due to increased depreciation as a result of recent investments and increased salary and wages, offset by lower annual incentive compensation. Efforts remain focused on the continued investment in elastomeric packaging components, formulation development, drug containment systems, self-injection systems and drug administration consumable.

All of the R&D costs incurred during 2024, 2023 and 2022 related to Proprietary Products.

The following table presents SG&A costs, consolidated and by reportable segment and corporate and unallocated items:

Consolidated SG&A costs decreased by $14.9 million, or 4.2%, in 2024, including a favorable foreign currency translation impact of $0.5 million, primarily due to lower annual incentive compensation and a decrease in expense related to stock-based compensation, partially offset by increased salary and wages.

Proprietary Products – Proprietary Products SG&A costs decreased by $9.1 million, or 3.8%, in 2024, including a favorable foreign currency translation impact of $0.5 million. Proprietary Products SG&A costs decreased primarily due to lower annual incentive compensation, partially offset by increased salary and wages.

Contract-Manufactured Products – Contract-Manufactured Products SG&A costs increased by $1.8 million, or 7.4%, in 2024, primarily due to increased salary and wages.

Corporate and unallocated items – Corporate SG&A costs decreased by $7.6 million, or 8.6%, in 2024, due primarily to a decrease in expense related to stock-based compensation, lower annual incentive compensation and decreased fees related to professional services, partially offset by increased salary and wages.

The following table presents other expense and income items, consolidated and by reportable segment and corporate and unallocated items:

Other expense and income items consist of a loss on disposal of plant, asset impairments, foreign exchange transaction gains and losses, contingent consideration and miscellaneous income and charges.

Consolidated other expense (income) changed by $10.4 million in 2024 as compared to 2023, due to the factors described below.

Proprietary Products – Proprietary Products other expense (income) changed by $7.2 million in 2024 as compared to 2023, primarily due to increased losses on foreign exchange transactions and increased expense related to contingent consideration being recorded in 2024, as compared to 2023.

Contract-Manufactured Products – Contract-Manufactured Products other expense (income) remained consistent in 2024 as compared to 2023.

Corporate and unallocated items – Corporate and unallocated items changed by $17.6 million in 2024 as compared to 2023. This is primarily due to the Company recording expense of $11.6 million as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment during 2023, which was not repeated in 2024. Additionally, the Company recorded additional asset impairments related to our cost method investments in 2023, as compared to 2024.

The following table presents operating profit and adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:

Consolidated operating profit decreased by $106.1 million, or 15.7%, in 2024, including an unfavorable foreign currency translation impact of $1.6 million, due to the factors described above.

Proprietary Products – Proprietary Products operating profit decreased by $132.3 million, or 18.6%, in 2024, including an unfavorable foreign currency translation impact of $1.6 million, due to the factors described above, most notably lower gross profit driven by lower sales volume and an unfavorable mix of products sold.

Contract-Manufactured Products – Contract-Manufactured Products operating profit increased by $0.2 million, or 0.3%, in 2024, due to the factors described above, most notably the increased sales prices.

Corporate and unallocated – Excluding the unallocated items, Corporate costs decreased by $14.3 million, or 15.6%, in 2024, due to the factors described above, most notably the decrease in expense related to stock-based compensation and lower annual incentive compensation.

For unallocated items, please refer to the Financial Performance Summary section above for details.

The following table presents interest expense, net, by significant component: